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Abstract
Background: Although overexpression of nitric oxide synthases (NOSs) has been found associated with prostate diseases,
the underlying mechanisms for NOS-related prostatic diseases remain unclear. One proposed mechanism is related to
the S-nitrosylation of key regulatory proteins in cell-signaling pathways due to elevated levels of NO in the prostate.
Thus, our primary objective was to identify S-nitrosylated targets in an immortalized normal prostate epithelial cell line,
NPrEC.
Methodology/Principal Findings: We treated NPrEC with nitroso-cysteine and used the biotin switch technique followed
by gel-based separation and mass spectrometry protein identification (using the LTQ-Orbitrap) to discover S-nitrosylated
(SNO) proteins in the treated cells. In parallel, we adapted a peptide pull-down methodology to locate the site(s) of S-
nitrosylation on the protein SNO targets identified by the first technique. This combined approach identified 116 SNO
proteins and determined the sites of modification for 82 of them. Over 60% of these proteins belong to four functional
groups: cell structure/cell motility/protein trafficking, protein folding/protein response/protein assembly, mRNA splicing/
processing/transcriptional regulation, and metabolism. Western blot analysis validated a subset of targets related to disease
development (proliferating cell nuclear antigen, maspin, integrin b4, a-catenin, karyopherin [importin] b1, and elongation
factor 1A1). We analyzed the SNO sequences for their primary and secondary structures, solvent accessibility, and three-
dimensional structural context. We found that about 80% of the SNO sites that can be mapped into resolved structures are
buried, of which approximately half have charged amino acids in their three-dimensional neighborhood, and the other half
residing within primarily hydrophobic pockets.
Conclusions/Significance: We here identified 116 potential SNO targets and mapped their putative SNO sites in NPrEC.
Elucidation of how this post-translational modification alters the function of these proteins should shed light on the role of
NO in prostate pathologies. To our knowledge, this is the first report identifying SNO targets in prostate epithelial cells.
Citation: Lam YW, Yuan Y, Isaac J, Babu CVS, Meller J, et al. (2010) Comprehensive Identification and Modified-Site Mapping of S-Nitrosylated Targets in Prostate
Epithelial Cells. PLoS ONE 5(2): e9075. doi:10.1371/journal.pone.0009075
Editor: Andy T. Y. Lau, University of Minnesota, United States of America
Received September 11, 2009; Accepted January 17, 2010; Published February 5, 2010
Copyright:  2010 Lam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Research supported in part with National Institutes of Health (www.nih.gov) grants ES006096, CA015776, CA062269, CA112532, and ES015584 (to
SMH), and GM067823 (to JM), and internal funding support from the Department of Environmental Health, College of Medicine, of the University of Cincinnati.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: shuk-mei.ho@uc.edu
Introduction
Evidence suggesting that an impaired nitric oxide (NO)-
signaling contributes to the pathogenesis of benign prostatic
hyperplasia (BPH) and prostate cancer (PCa) is accumulating. This
view lends supports to the postulate that chronic prostatic
inflammation is an inciting factor for BPH and PCa [1,2] or that
proliferative inflammatory atrophy is the precursor of PCa [3].
Nevertheless, studies of this relationship remain sparse and the
major findings are limited to a few reports of an aberrant
expression of the inducible nitric oxide synthase (iNOS or NOS-2)
in diseased prostate tissues [4–7].
While endothelial NOS and neuronal NOS constantly generate
a basal level of NO, iNOS produces NO upon stimulation with the
inflammatory cytokines, IL-2, TNF-a and IL-1b; hypoxia; and
other stimuli. Thus, the induced levels of NO are highly dependent
on the redox environment and the signals received by the cell.
Immunohistologic studies demonstrated that iNOS is not
expressed in normal prostate [8] but that the enzyme is expressed
in all specimens with BPH, low- or high-grade prostatic intra-
epithelial neoplasia (PIN), and PCa. iNOS immunoreactivity was
found to be higher in high-grade PIN and PCa than in BPH and
low-grade PIN. In both BPH and PIN, immunopositivity was
localized to both basal epithelial cells and secretory cells of the
glandular epithelium, along with weak staining in smooth muscle
cells [8], whereas both PCa and its surrounding inflammatory cells
expressed high levels of iNOS. Production of high levels of NO by
iNOS causes nitrosative stress (NS), which is consistent with a role
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proposed to promote the development of prostate disease, partly
by imparting damage to DNA, proteins, and lipids [3,9–12], we
lack a clear understanding of the mode of action of NS, despite
recent reports suggesting that the aggressiveness of PCa cell lines
can partly be determined by NO [13,14]. In particular, the impact
of NS on normal prostatic epithelial cells with regard to
early stages of disease development is unknown and warrants
investigation.
Traditionally, NO has been demonstrated to act through the
guanylate cyclase/cGMP signaling pathway to regulate many
physiological processes [15,16]. However, through reversible S-
nitrosylation of cysteine residues on specific regulatory proteins,
NO has the unique function of affecting cell survival and death,
mostly reported for endothelial cells and neurons [17,18]. NO
generated by NOS reacts with intracellular glutathione to form
nitrosoglutathione, an intracellular reservoir, which in turn trans-
nitrosylate protein thiol to form nitrocysteine, thus modifying
protein functions [19]. A number of signal transduction molecules,
including those participating in apoptosis (e.g., Bcl-2, caspase-3,
GAPDH, TRAIL receptor DR4, NFkB, RAC/p21, and Ras),
have been identified as targets of S-nitrosylation and their activity
and/or stability is affected by overproduction of NO [17,20].
Additionally, NO has been shown to inhibit 8-oxodeoxyguanosine
DNA glycosylase, a DNA repair enzyme, via S-nitrosylation,
which may allow DNA damage to accumulate during cell
proliferation, linking chronic inflammation to carcinogenesis
[21,22]. Therefore, high output of NO due to iNOS over-
expression in the normal prostatic epithelial cells and/or their
neighboring inflammatory cells will likely nitrosylate key prostatic
proteins responsible for the pathogenesis of prostate diseases,
including BPH and PCa.
The biotin switch technique (BST) developed by Jaffrey et al.
[23] is now an established method for analyzing protein S-
nitrosylation. BST allows S-nitrosylated proteins (protein-SNOs) to
be detected in a complex mixture such as a cell lysate. However,
most profiling studies using BST identified the protein-SNOs but
did not report the site of modification. A few recent studies have
incorporated an additional procedure involving a peptide pull-
down step followed by LC-MS/MS sequencing to identify the site
of modification on the target proteins in various tissues and cell
types [24–27]. Yet, protein-SNO has not been identified in
prostate epithelial cells.
Our goal is to gain new insights into the role of NS in the
development of prostate diseases by comprehensively identifying
these targets and their modification sites in an immortalized
normal prostate epithelial cell line (NPrEC) using a protein and
peptide pull-down combination protocol. We here identified 116
protein-SNO in the NPrEC and determined the sites of
modification for 82 of them. Over 60% of the proteins belong to
the functional categories of cell structure/cell motility/protein
trafficking, protein folding/protein response/protein assembly,
mRNA splicing/processing/transcriptional regulation, and me-
tabolisms. We also have used bioinformatic approaches to analyze
the SNO sequences in terms of primary and secondary struc-
tures, solvent accessibility, and three-dimensional (3-D) structural
analysis for those whose protein structures are available. Western-
blot analysis validated the S-nitrosylation status of a subset of
targets related to cancer development. Bioinformatics revealed
that 79% of the SNO sites that can be mapped into resolved
structures are fully buried, among which half have charged amino
acids in the 3-D neighborhood. Future functional elucidation of
these targets will yield insights into the role of NO, NS, and/or
inflammation in the development of prostate diseases.
Materials and Methods
Cell Culture
An immortalized normal prostate cell line (NPrEC) was
maintained in Defined Keratinocyte-SFM medium with growth-
promoting supplement (Invitrogen, Carlsbad, CA). Prostate cancer
cell line (PC3) was maintained in F12 medium with Kaighn’s
modification (F-12K), 4 mM L + glutamine (ATCC, Manassas,
VA) and 10% fetal bovine serum. Cell cultures were maintained at
37uC in a humidified incubator with 5% CO2. S-nitroso-L-
cysteine (CysNO) was freshly synthesized by mixing equimolar
concentrations of NaNO2 in water and cysteine in 1 N HCl
followed by incubation at room temperature for 30 min and
neutralization with an equal volume of HEN buffer (250 mM
HEPES-NaOH, 1 mM EDTA, and 0.1 mM neocuproine,
pH 7.8) [28]. NPrEC were seeded in 150-mm dishes and treated
with 1 mM CysNO from a 250 mM CysNO stock solution for
15 min in the dark. The dose of CysNO (1 mM) selected was
based on previous studies of endothelial cells [28]. After 15 min,
the cells were harvested by scraping. The cell pellets were washed
twice with 1x phosphate buffer saline (PBS) and stored frozen until
protein extraction.
Cell Transfection
PC3 cells (1610
6) were transfected in 10-cm dishes using Mirus
TransITH-Prostate Transfection Kit (MirusBio Corp. Madison,
WI) with 24 mg of iNOS expression plasmid (BC130283; TOPO
pcDNA 3.1) for 24 hr prior to harvest. Cells were harvested with
scraping using 1x PBS/1 mM EDTA/0.1 mM neocuproine and
the pellet stored at 280uC.
Biotin Switch Technique (BST)
The biotin switch technique was performed as previously
described [23,29,30]. The cell pellet was lysed with HEN buffer/
1% Triton X-100, with the addition of protease inhibitor (Roche,
Basel, Switzerland) except for those samples used for biotinylated
peptide capture. The protein concentration was adjusted to 0.7–
1 mg/mL. As the first step of BST, free cysteine thiols were
blocked by S-methylthiolation by adding methyl-methane thio-
sulfonate (MMTS) [2 M in dimethylformide (DMF)] to a final
concentration of 100 mM in the presence of 2.5% SDS at 50uC
for 30 min. Two volumes of acetone were added, followed by
incubation at 220uC for 20 min to precipitate the protein. The
pellet was then washed four times with 70% acetone and then
resuspended in 1% SDS in HEN/10 buffer. The SNOs were then
converted to thiols via transnitrosation with ascorbate before the
nascent thiols were biotinylated with biotin-HPDP, a reactive
mixed disulfide of biotin. Specifically, biotinylation was performed
by adding 1/10 volume of 4 mM biotin-HPDP (Pierce) in DMSO
(prepared from a 50 mM stock in DMF) in the presence or
absence of 100 mM freshly prepared sodium ascorbate (NaAsc;
Fluka) in HEN/10 buffer [29], and incubated at room
temperature for 1 h. The assay was performed in amber tubes
with minimal light exposure. Gel electrophoresis was performed
after biotinylation with non-reducing sample buffer to detect
biotinylated proteins.
Purification of Biotinylated Proteins
After biotinylation, proteins were precipitated with acetone;
protein pellets were washed with 70% acetone four times and
resuspended in 250 mL of 25 mM HEPES/1 mM EDTA/1%
SDS; 750 mL of neutralization buffer (25 mM HEPES/1 mM
EDTA/1% Triton X/100 mM NaCl) was added to the sam-
ples, followed by centrifugation to remove insoluble aggregates.
Nitrosylation in the Prostate
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Rockford, IL) was used to pull down biotinylated proteins at
room temperature for 2–3 h (Pierce; 50 mL dried beads per 1 mg
of initial starting material). After pull-down, the beads were
washed four times with five volumes of neutralization buffer with
500 mM NaCl, followed by two washes with five volumes of
neutralization buffer. The protein was eluted with two dry-bead
volumes of 25 mM HEPES/1 mM EDTA/100 mM b-mercap-
toethanol at room temperature for 30 min with shaking. The
protein was then concentrated by Microcon (10,000 MWCO,
Millipore, MA), heated at 95uC with reducing sample buffer,
loaded onto SDS-PAGE (Ready Gel, Biorad), followed by western-
blot analysis or stained with silver (Invitrogen, Carlsbad, CA) or
Coomassie Blue (Biorad, Hercules, CA).
Capture of Biotinylated Peptides
S-nitrosylated peptides were captured as previously described
[25]. In brief, 1 mg of protein was used for BST and after MMTS
blocking, biotinylation, and acetone precipitation, protein pellets
were resuspended in 500 mL of 100 mM NH4HCO3/10% ACN
and incubated with 50 mg (per 1 mg of protein) of trypsin at 37uC
for 18 h. The resulting digest was passed through a Microcon
(10,000 MWCO, Millipore, MA), followed by pull-down with
NeutrAvidin agarose resin (50-mL beads) at room temperature for
30 min. The precipitate was washed five times with 10 volumes of
1MN H 4HCO3 and five times with 10 volumes of water. Elution
was performed by incubating the beads with 75 mL of 70%
formic acid for 30 min. The eluate was evaporated to 2 mL and
resuspended to 10 mL with 2% ACN/0.1% FA. Half of the sample
was subjected to LC/MS.
Gel Electrophoresis and Western Blot Analysis
SDS-PAGE was performed with ReadyGel 4–15% (Biorad,
Hercules, CA) or Precise protein gel 8 or 12% (Pierce, Rockford,
IL). After electrophoresis, gels were transferred onto a PVDF
membrane (Immobilon FL, Millipore, MA) with a blotting cell
(Invitrogen, Carlsbad, CA) at 30 V for 2 h. Primary antibodies
were used with the following conditions: mouse monoclonal
proliferating cell nuclear antigen (PCNA) (Santa Cruz sc-56;
1:1000, 1 h at RT); mouse monoclonal maspin (BD Pharmingen;
1:500, O/N at 4uC); integrin b4 (Santa Cruz; 1:1000, O/N at
4uC); a-catenin (BD Pharmingen; 1:500, O/N at 4uC); karyo-
pherin b1 (Santa Cruz (H-300), 1:1000, O/N at 4uC]; mouse
monoclonal elongation factor 1 alpha (EF1a) (Upstate, CA;
1:1000, O/N at 4uC), which recognizes both EF1A1 and
EF1A2; streptavidin Alexa Fluor 680 (Invitrogen; 1:1000, 1 h at
RT). IRDye antibiotin was used at 1:1000 overnight, and
corresponding IRDye conjugated secondary antibodies (Rockland,
PA) were used at 1:5000 dilutions. Starting material of 1 mg was
used for western-blot confirmation.
Tryptic Digestion and LC-MS/MS
Tryptic digestion was performed as described previously [31,32].
In brief, silver-stained gel bands were excised and destained with a
50 mL of a 1:1 mixture of 30 mM potassium ferricyanide (Sigma,
MO) and 100 mM sodium thiosulfate (Sigma) in a siliconized tube
until the brownish stain disappeared (,5 min), whereas CBB-
stained gel bands were destained with 50% ACN/MeOH/5%
acetic acid for 4 h, followed by 50% ACN/50 mM NH4HCO3 for
2–3 h. After the gel pieces were washed with 40 mM NH4HCO3,
they were minced, dehydrated with ACN, dried in a SpeedVac,
and subjected to digestion with Trypsin Gold (Promega, Madison,
WI) for 18 h at 37uC. Peptides were extracted successively with 1%
FA/50% ACN, 80% ACN/1% FA, and 100% ACN and then
purified by ZipTip (Millipore, MA). Each digest was analyzed
by capillary LC-MS/MS with a Finnigan LTQ-Orbitrap (Thermo
Fisher Scientific, MA). Half of the digest was loaded directly onto
the 75 mm6100 mm PicoFrit capillary column (New Objective,
MA) packed with MAGIC C18 (100 A ˚ 5 m, Michrom Biore-
sources, CA) at a flow rate of ,300 nL/min, and peptides
were separated by a gradient comprising 2–60% ACN/0.1% FA
in 30 min, 60–98% ACN/0.1% FA in 4 min, and held at
98% ACN/0.1%FA for 2 min. The LTQ-Orbitrap was oper-
ated in standard data-dependent ‘‘top-three’’ mode with lock
mass function activated (protonated polydimethylcyclosiloxane
[Si(CH3)2O))6; m/z 445.120025)]. A survey scan from m/z 300–
1600 at 60,000 resolution in the Orbitrap was paralleled by 3 MS/
MS scans in the LTQ. Exclusion duration was set for 3 min. The
minimum signal threshold was 250. Singly charged ions were
excluded for MS/MS.
Data Analysis
The product ion spectra were searched against the latest version
of the human subset of the International Protein Index (IPI)
database containing sequences in forward and reverse orientations
(v3.56, Mar 09, target-decoy) using the SEQUEST search engine
in Bioworks 3.3. The database was indexed with fully enzymatic
activity and two missed cleavage sites allowed for trypsin; peptides
MW of 600–6000. SEQUEST search parameters were as follows:
mass tolerance of 15 ppm and 1 amu for precursor and fragment
ions, respectively; three differential/post-translational modifica-
tions allowed per peptide; variable modification on methionine
[+15.9949 amu for oxidized methionine and +45.98772 amu
(MMTS) on cysteine]. For biotinylated peptides, variable modi-
fications of +428.191567 amu (HPDP-biotin) were included to
allow identification of the site of modification. Analysis was
performed in Bioworks 3.3 by applying filters of XCorr [2.0 (2+),
2.5(3+)]; DelCN ($0.1)], SP./=300, and precursor mass
accuracy #15 ppm. Protein identifications were ranked by protein
probability P (pro), and the false positive rate was limited to ,1%
FP. The MS/MS spectra of biotinylated peptides were evaluated
by Scaffold (Proteome Software, OR).
Protein Classification
Identified S-nitrosylated proteins were then classified by the
PANTHER system (www.pantherdb.com) on the basis of their
unique gene IDs. The classification system provides information
on the candidates regarding their molecular function and the
biological processes and signal transduction pathways to which
they belong.
Mapping S-Nitrosylated Sites into High-Resolution PDB
Structures
The initial set comprising 82 proteins with 141 S-nitrosylated
cysteines was analyzed to identify sites that can be mapped into
structurally resolved proteins and consequently assessed by their
structural context. This process was facilitated by automated
mapping into the PFAM database of protein domains and the
Protein Data Bank (PDB) of structurally resolved proteins, using
SCORPPION (http://scorppion.cchmc.org) and POLYVIEW-3D
(http://polyview.cchmc.org/polyview3d.html) servers [33]. Struc-
turally resolved fragments or domains of 35 proteins, or their
sufficiently close homologs (we used a BLASTp E-value of ,10E-
50 and sequence identity of .90%) with conserved SNO sites, have
been identified in PDB. Since PDB structures often cover only
part of the target sequence, 43 SNO sites in 24 proteins were
subsequentlymappedintoresolved fragments.Furthervalidationof
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(http://ca.expasy.org/prosite/) searches. Residues and atoms in
contact with SNO cysteines were identified with the iMolTalk
server (http://i.moltalk.org/) and the Loopp program [34], with a
cutoff distance of 5 A ˚ from the sulfur atom of the cysteine. These
protein structures, together with the location of S-nitrosylated
cysteines, are listed in Supporting Information Table S2.
Sequence-Based Bioinformatic Analysis of Cysteine-
Containing Peptides
To further assess sequence motifs and propensity for secondary
structure and solvent exposure states for all (and not only
structurally resolved) SNO proteins, we used sequence-based
analysis and prediction methods. In particular, we used the
SABLE server (http://sable.cchmc.org) [35] to predict from
sequence secondary structures and solvent accessibilities, with
the goal of identifying potential characteristics of SNO sites in
terms of structural profiles. We analyzed sequence motifs around
S-nitrosylated cysteines with WebLogo (http://weblogo.berkeley.
edu/). In addition, we computed frequencies of amino acid
residues with reduced alphabets (e.g., hydrophobic vs. hydrophilic)
within windows of up to 21 residues centered at the S-nitrosylated
cysteines. The search for putative sequence motifs was performed
with the MEME (http://meme.nbcr.net) and PRATT (http://
www.ebi.ac.uk/Tools/pratt/index.html) servers.
Results
1. Identification of Protein Targets of S-Nitrosylation
The BST was performed, and its specificity in NPrEC was
demonstrated as described below. Western-blot analysis (Figure 1)
of protein S-nitrosylation in NPrEC noted a strong anti-biotin
immunoreactivity for biotinylated proteins only in cells treated
with CysNO but not in untreated control cells (CNTL), indicating
a complete blocking of free cysteine thiols by MMTS and mini-
mal endogenous S-nitrosylation in untreated cells. The absence
of a signal in reactions without NaAsc demonstrates that the
modification is SNO-specific [29]. After pull-down of the protein-
SNOs and SDS-PAGE, distinct bands were clearly visible on the
silver-stained gels in the CysNO lane but not in the CysNO minus
NaAsc and control lanes (Figure 1B). These data are in accordance
with results of the western-blot analysis (Figure 1A), indicating
specific pull-down of biotinylated proteins.
After establishing the efficacy and specificity of the BST in
NPrEC, we used the scheme depicted in Figure 2A in an effort to
comprehensively identify S-nitrosylation targets at the protein
(Approach 1) and peptide (Approach 2) levels. The identification
(ID) was deemed to be a target of S-nitrosylation 1) if it was
identified in the CysNO-treated samples but not in the untreated
control samples in two dependent protein pull-down experiments,
or 2) if it was identified in one of the two protein pull-down
experiments and the corresponding biotinylated peptide(s) were
identified in the peptide pull-down. With the mass tolerance on
peptide precursor ,15 ppm and the false positive (FP) rate ,1%
in database searching, as well as the conventional peptide filters
(XCorr 1.5, 2.0, 2.5, DCn.0.1, Sp.300), we identified 195 and
134 unique protein-SNOs in the two protein pull-downs from two
independent cell culture experiments (Pull-Down I and Pull-Down
II), respectively, with 60 of them shared by the two data sets
(Figure 2B, Supporting Information Table S1A). After identifying
the nitrosylated proteins by Approach 1, we looked for the
corresponding peptide-SNOs from multiple peptide pull-downs
Figure 1. S-nitrosylation in NPrEC. A) Normal prostate cells, NPrEC, were treated with or without 1 mM CysNO followed by a biotin BST. Protein
extract (100 mg) was loaded onto an SDS-PAGE (10%). Western-blot analysis was carried out, and the membrane was probed with anti-biotin. B) After
cell treatment (1 mM CysNO) and the biotin switch assay, neutravidin pull-down and SDS-PAGE (4–15%) was performed (3 mg was used for IP in each
lane). Each lane (CNTL, CNTLDNaAsc, CysNO, CysNODNaAsc) was divided into five portions (I–V) as indicated and subjected to tryptic digestion and
mass spectrometry protein identification.
doi:10.1371/journal.pone.0009075.g001
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down II, 24 had the corresponding biotinylated sequences (one or
multiple biotinylated peptides) determined in the peptide pull-
down experiments (Figure 2B, Supporting Information Table
S1B). Moreover, we were able to obtain from the peptide pull-
downs biotinylated sequences for 56 protein-SNOs that were
identified in either one of the protein pull-downs (Figure 2B,
Supporting Information Table S1B). All together, we identified
116 distinct protein SNOs [60 IDs (that are present in both
protein pull-downs) and 56 IDs (that are present in one protein
pull-down with a corresponding biotinylated peptide(s) found in
peptide pull-downs)]. All the biotinylated peptides identified have
a precursor mass accuracy ,5 ppm (Supporting Information
Tables S1A and S1B). The MS/MS spectra for all the biotinylated
peptides identified are provided in Supporting Information Figure
S1. Literature references are included in Tables S1A and S1B if
the protein and/or the cysteine sites have been reported to be S-
nitrosylated.
2. Classification of the Nitrosylated Proteins Identified
The identified proteins were classified into different categories
on the basis of their function according to the Panther classification
system (Figure 3). Over 60% of the S-nitrosylated proteins belong
to one of the four major functional categories: cell structure/cell
motility/intracellular protein trafficking (20%), protein folding/
stress response/protein assembly (16%), RNA splicing/processing/
transcription regulation (13%), and metabolisms (12%).
Cell structure/cell motility/intracellular protein trafficking represents the
largest category with proteins having distinct molecular functions,
e.g., cell-structure components [plectin 1 (PLEC1), vimentin
(VIM), actinin 1, 4 (ACTN1, ACTN4)], intracellular protein
trafficking and motility [tubulin beta 2c (TUBB2C), annexin A1, 2
(ANXA1, ANXA2), reticulon 4 (RTN4), PDZ and LIM domain,
elfin (PDLIM1), tropomyosin 1 (TPM1)], nucleotransport [kar-
yopherin (importin)b1 (KPNB1)], and exocytosis/endocytosis/
transport [valosin-containing protein (VCP), actin beta (ACTB),
and actin alpha 2 (ACTA2)].
Under protein folding/stress response/protein complex assembly are
chaperonin-containing TCP subunits (CCT3, CCT4, CCT5,
CCT7), t-complex 1 (TCP1), heat-shock 60-kDa protein 1
(HSPD1), heat-shock 70-kDa protein 4 (HSPA4), heat-shock
protein 70-kDa protein (HSPA5, HSPA8, and HSPA9), heat-
shock protein 90 kDa alpha (HSP90AA1), heat-shock protein 90-
kDa alpha class B member 1(HSPAB1), heat-shock protein 90-
Figure 2. Identification of S-nitrosylated proteins. A) Schematic of the workflow. Approach 1. Protein extracted from NPrEC treated with
CysNO (1 mM) was subjected to a BST, and nitrosylated proteins were purified by Neutravidin pull-down, followed by SDS-PAGE. Nitrosylated
proteins were identified by tryptic digestion and LC-MS/MS in the five gel bands (I–V) of lanes (CNTL, CNTLDNaAsc, CysNO, CysNODNaAsc) according
to the defined peptide selection criteria (XCorr 1.5, 2.0, 2.5, DCn.0.1, Sp.300, precursor ,15 ppm, with ,1% FP). After the protein-SNOs were
identified, their sites of modification in peptide (peptide SNO) were identified in approach 2: after biotin switching, 1 mg of protein was digested and
the nitrosylated peptides were pulled down and subjected to mass spectrometric site mapping, according to the same peptide selection criteria. B)
Number of protein-SNO and peptide-SNO identification: Protein pull-downs from two independent experiments were performed to identify protein-
SNOs, followed by the identification of the corresponding peptide-SNOs from peptide pull-downs. A total of 116 proteins were identified, with the
sites of modification determined for 82.
doi:10.1371/journal.pone.0009075.g002
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which HSPA5, A8, and A9 are involved in an apoptotic pathway
and HSPB1, in the p38 MAPK pathway.
Grouped under RNA splicing/processing/transcription regulation
are those proteins related to mRNA splicing [heterogeneous
nuclear ribonucleoprotein (HNRPDL, HNRNPR, HNRNPA1),
RNA-binding motif protein 39 (RBM39), DEAH box polypep-
tide 9 (DHX9), U2 small nuclear RNA auxiliary factor 2
(U2AF2), KH-type splicing regulatory protein (KHSRP)], mRNA
transcription and processing [general transcription factor II, I
(GTF2I), RuvB-like 1 (RUVBL1), TAR DNA-binding protein
(TARDBP), heterogeneous nuclear ribonucleoprotein (HNRNPK,
HNRNPM)], and chromatin remodeling [SWI/SNF regulator of
chromatin, subfamily c, member 2 (SMARCC2)].
Under the category of metabolisms, we found proteins belonging
to the glycolysis pathway [phosphoglycerate kinase 1 (PGK1),
enolase 1 (ENO1), aldolase A (ALDOA), pyruvate kinase (PKM2),
glucose phosphate isomerase (GPI), triosephosphate isomerase,
(TPI1)], tricarboxylic acid cycle [citrate synthase (CS), aconitase 2
(ACO2), malate dehydrogenase 2 (MDH2)], amino acid metab-
olism [(aldehyde dehydrogenase 18 family, member A1
(ALDH18A1)], purine metabolism [IMP dehydrogenase
(IMPDH2), adenylate kinase 2(AK2)], porphyrin metabolism
[HMOX2 (heme oxygenase)], and fatty acid/lipid/steroid metab-
olism [farnesyl-diphosphate farnesyltransferase 1 (FDFT1), an-
nexin A1 (ANXA1)].
Worth noting is a group of signal transduction proteins. Among
them, although only 14-3-3 theta polypeptide (YWHAQ) is
classified exclusively in signal transduction; a number of pro-
teins are classified in other categories but often are associated
with various signaling transduction pathways, including integrin
signaling [integrin (ITGB4, ITGA6) filamin (FLNA, FLNB,
FLNC), actinin alpha 1, 4 (ACTN1, ACTN4)], cadherin signaling
[a-catenin (CTNNA1)], EGF signaling (epidermal growth factor
receptor (EGFR), FAS signaling [lamin (LMNA, LMNB1)], as well
as the and the tumor suppressor maspin (SERPINB5). Some are
involved in DNA replication [proliferating cell nuclear antigen
(PCNA), X-ray repair complementing defective repair (XRCC5)],
cell-cycle regulation and cell proliferation [N-myc downstream-
regulated 1 (NDRG1)], protein phosphorylation [protein phos-
phatase 1G (2C) (PPM1G)], as well as cell adhesion and induction
of apoptosis [galectin 1 (LGALS1), glyceraldehyde-3-phosphate
dehydrogenase GAPDH].
Finally, other classified proteins include those that share
common functions in antioxidation and free-radical removal
include isomerases [peroxiredoxin (PRDX1, PRDX5), protein
disulfide-isomerases (PDIA3, PDIA6), proline 4-hydroxylase, beta
peptide (P4HB)], those related to protein biosynthesis and
translation regulation [eukaryotic translation initiation factor 2
subunit 3 (EIF2S3), eukaryotic translational elongation factor 2
(EEF2), ribosomal protein L5 (RPL5), Tu translation elongation
factor, mitochondrial (TUFM), ribosomal protein S3 (RPS3),
ribophorin I (RPN1), eukaryotic translation elongation factor 1
alpha 1 (eEF1A1)], and those belong to proteolysis [(proteasome
activator subunit 1 (PSME1), calpastatin (CAST)], serpin pepti-
dase inhibitor clade H (SERPINH1)] and ion transporter category
Figure 3. Protein-SNO classification. Proteins that were identified as nitrosylated are grouped according to the biological processes they belong
to according to the Panther classification system and listed in Tables S1A and S1B with their biotinylated peptides, if available.
doi:10.1371/journal.pone.0009075.g003
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VDAC3), chloride intracellular channel 1 (CLIC1), and ATPase
Ca
++ transporting (ATP2A2)].
3. Confirmation of Nitrosylated Targets by Western Blot
Analysis
We selected a subset of the identified targets that are related to
cancer development (promotion or progression) and for which
antibodies are commercially available for western-blot analysis
(Figure 4). We confirmed the S-nitrosylation status of proliferating
cell nuclear antigen (PCNA), maspin (serpin B4), integrin b4, a-
catenin, karyopherin (importin) b1, and elongation factor 1A
(eEF1A). The targets were pulled down and recognized by their
respective antibodies in cell lysates prepared from NPrEC treated
with CysNO but not in those prepared in the absence of NaAsc or
in lysates of untreated controls.
4. Confirmed Targets Are Endogenously Nitrosylated
We further investigated if the protein-SNOs identified could be
nitrosylated by iNOS overexpression. We transiently transfected
an iNOS expression plasmid into PC3 cells and assessed the
nitrosylation status of the protein targets previously identified
with CysNO treatment. PC3 cells were used due to its higher
transfection efficiency than NPrEC. The overall increased protein
nitrosylation in PC3 cells expressing iNOS is shown in Figure 4B.
The anti-biotin reactivity is specific to iNOS expressing PC3 cells
(as compared to untransfected PC3 cells), and is SNO-specific (as
the anti-biotin signal was diminished in the reaction without
NaAsc). All the proteins selected for confirmation, except for alpha
catenin (which does not express in PC3 cells), were shown to be
nitrosylated after iNOS overexpression. The extent of nitrosylation
was reduced in reactions without NaAsc (Figure 4C) demonstrat-
ing its SNO specificity.
Figure 4. Verification of nitrosylated proteins. A) Western blot analysis of targets nitrosylated by CysNO. NPrEC were treated with
1 mM CysNO, and 1 mg of protein extract was subjected to BST. Biotinylated proteins were pulled down with Neutravidin beads, eluted with b-
mercaptoethanol, concentrated and detected using western blot. 8% of total protein was loaded as input, and the same membrane was probed with
respective antibodies with stripping and re-probing. B) Protein nitrosylation in iNOS expressing PC3 cells. PC3 cells were transiently
transfected with an iNOS expressing plasmid. Cells were harvested 24 h post-transfection. 3.5 mg of total protein was subjected to BST, as described
in Materials and Methods. After BST, the overall protein nitrosylation was assessed by western blot using an anti-biotin antibody. The membrane was
stripped and re-probed with GAPDH to show equal loading. C). Endogenous nitrosylation of protein targets. Biotinylated proteins were pulled
down with Neutravidin and analyzed by Western blot. Seventy mg was loaded as input, and the same membrane was probed with respective
antibodies with stripping and re-probing.
doi:10.1371/journal.pone.0009075.g004
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Methods
We performed bioinformatic analysis of the 141 SNO sites
(from the 82 protein-SNOs) by several sequence motif detection
methods, including secondary structure and solvent accessibility
predictions and hydrophobicity analysis (as described in Mate-
rials and Methods). These analyses did not reveal any clear
signatures of SNO sites as compared with a set of cysteine
residues derived from a representative set of ,1,300 proteins
(data not shown).
6. Mapping SNO Sites into High-Resolution PDB
Structures and Analysis of Structural Features
Since some of the 141 SNO sites identified in this (and previous
global site-mapping studies) could represent S-nitrosylation events
without clear functional relevance, we performed a comprehensive
mapping of SNO sites into structurally resolved protein domains
with the use of PFAM and PDB databases to obtain a
representative data set for further bioinformatics analyses. As
proteins (and their domains) that are a focus of intensive experi-
mental (and in particular structural) studies are more likely to
occur in PDB, SNO sites within these domains/proteins are also
more likely to represent functionally relevant modifications. We
mapped 42 SNO sites in 24 different proteins into high-resolution
structures, with some of them having been reported to be
nitrosylated and/or the sites having been located (Supporting
Information Table S2).
For the 42 SNO sites that can be mapped into PDB structures,
we found no clear sequence motif around the sites (shown at the
center of the window of 21 residues) (Figure 5). Similarly, we
observed no clear biases in terms of secondary structures.
Specifically, we observed all three states (helix–H, beta-strand–
E, other–C), with frequencies of ,0.24, 0.32, and 0.45, for H, E,
and C, respectively, values similar to the frequencies of 0.24, 0.36
and 0.40 found in a large set of ,1,300 representative structures
derived from PDB (Supporting Information Table S3). Regarding
solvent accessibility, ,79% (34 sites) of SNO cysteines that can be
mapped into resolved structures are fully buried (even though SH
groups are just under the surface in some cases), in contrast with
,56% for a set of cysteines derived from ,1,300 representative
structures (Supporting Information Table S3). About half of these
buried sites (see Supporting Information Table S4 for detailed
annotation of each case) are characterized by a purely
hydrophobic environment without charged residues in the direct
vicinity.
7. Localization of Neighboring Charged Residues in the
Vicinity of the SNO
On the basis of previous reports that nitrosylation may be
facilitated by the presence of charged residues in the vicinity of an
SH group [36,37], we then determined the neighboring amino
acids within 5 A ˚ of the cysteine nitrosothiols. We found that 17
sites, of the 34 that are fully buried, are characterized by the
presence of positively and/or negatively charged residues within
the 3-D neighborhood of SNO. An example of such a case
(Figure 6A) is that in which a buried cysteine (C244) in protein
disulfide-isomerase, PDIA3 (PDB code 3F8U) is found in close
proximity with positively charged (R280) and negatively charged
(E216) residues. This site in PDIA3 is buried in the core of the
protein, implying that diffusion of NO through a thermally
fluctuating protein matrix would be required to S-nitrosylate the
buried cysteine residue. A likely diffusion path would involve the
E216 residue (shown in red in Figure 6A), which is partially
exposed and separates C244 from the solvent.
8. Structural Analysis Predicts That Nitrosylation Might
Affect the Function of Some Proteins
Although the functions of several mapped structures (e.g.,
GAPDH [38], peroxiredoxin [39]) have been shown to be affected
by nitrosylation (Supporting Information Table S2), structural
analysis on the mapped structures revealed that nitrosylation of
some of the newly found SNO sites might regulate the function of a
number of proteins. One of the representative examples is EGFR,
in which one of the targeted cysteines is located at the ligand-
binding interface in the extracellular domain. This domain has
been resolved in a complex with a monoclonal antibody inhibitor
(see Figure 6B) that partially occludes ligand-binding sites and
keeps the receptor in inactive conformation. S-nitrosylation of this
cysteine thiol in EGFR might therefore directly affect its interaction
with ligands and signal transduction in the EGFR pathway.
On the other hand, we found a number of SNO sites (including
three in direct contact with ligands, and five at protein-protein
interaction interfaces) that are accessible on the protein surface in
unbound forms. One example (Figure 6C) is that in which the
structure of PCNA complexed with p21 peptides that mediate
regulatory interaction with cdk/cyclin complexes; the S-nitrosy-
lated cysteine residues can be seen to be located within
trimerization interfaces of the PCNA trimer. S-nitrosylation of
PCNA might have an effect on the trimer formation and/or affect
protein interactions with cdk/cyclins and other proteins that
regulate DNA replication.
Figure 5. Frequency of amino acids surrounding S-nitrosylated cysteines in 42 sites mapped into structurally resolved domains
from 24 different proteins. Hydrophobic residues are shown in black; charged residues in red and blue, respectively; and hydrophilic residues in
magenta and green (for mixed-character residues).
doi:10.1371/journal.pone.0009075.g005
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In NPrEC, we identified 116 protein-SNOs, with modification
sites located for 86 of them by the use of a combined protocol
involving both protein and peptide pull-down following the BST.
Of the proteins identified, 60% belong to four functional
categories: cell structure/cell motility/intracellular protein traf-
ficking, protein folding/stress response/protein assembly, RNA
splicing/processing/transcription regulation, and metabolisms.
Thirty percent of the proteins identified have previously been
reported to be nitrosylated in non-prostate tissues, and certain
proteins have been shown to cause aberrant signaling processes
and/or been associated with disease development. For example,
several isomerases (triosephosphate isomerase 1 TIP1; glucose
phosphate isomerase GPI, protein disulfide isomerase family A,
member 3 and 6, PDI, proline 4-hydroxyase, P4HB) and oxidative
stress proteins (e.g., peroxiredoxin) were identified as nitrosylated,
among which SNO-PDI [40] and SNO-peroxiredoxin [39,41]
have been reported to serve as direct links between nitrosative/
oxidative stress and neurodegenerative diseases. Although NS has
been implicated in the pathogenesis of prostatic diseases [3,9–14],
its mechanism of action has not been established. The discovery of
these protein-SNOs in this study support the notion that,
depending on the level of NS, NO can induce modification on a
specific subset of proteins that may play a role in the pathogenesis
of prostate diseases.
A number of recent studies have described similar peptide pull-
down approaches for the profiling of nitrocysteine-containing
peptides in cells or lysates treated with either CysNO or
nitrosoglutathione (GSNO) [24–27,42]. Compared with these
studies, which identified nitrosylated targets on the basis of one
single biotinylated peptide, our study strengthened the stringency/
confidence of the peptide-SNO identifications by also identifying
the corresponding proteins in the protein pull-down. In fact, by
taking advantage of the high mass accuracy measurement of the
LTQ-Orbitrap, in our study, all the sequenced biotinylated
peptides (Table S1A and S1B) have a low precursor mass error ,
5 ppm (although a peptide mass tolerance was set to ,15 ppm
during database searching), strongly supporting our peptide-SNO
identifications. Of the sites of modification we identified in the
study, 16% have been reported in the literature. These sites,
together with the newly located sites, serve as a foundation for
future investigations of how NO regulates the functions of the
target proteins.
In our analysis of the 141 SNO sites, we did not find any
consensus sequence motif in terms of primary or secondary
structures. This is consistent with the previously reported results of
primary sequence analysis of SNO proteins, including an attempt
to derive predictive signatures by using machine-learning
approaches by Hao and colleagues [27]. On the other hand,
hydrophobicity analysis indicates that half of the SNO sites are
located within a hydrophobic pocket, which is also in agreement
with the findings of Greco and colleagues [25], who found that
most of the 18 SNO sites they analyzed were located in
hydrophobic pockets. We observed an enrichment of buried
cysteine residues (79%) in SNO proteins, which may be indicative
of the primary role of S-nitrosylation in regulating protein stability.
In fact, many studies have demonstrated that nitrosylation can
affect protein stability (e.g., HIF-1a [43], Bcl-2 [44])—some
through the ubiquitin-proteasome system. For the SNO sites that
can be mapped to structurally resolved structures, half of the
buried cysteines were surrounded by spatially adjacent charged
amino acids. Perez-Mato et al. first proposed an autocatalytic
mechanism of nitrosylation that is facilitated by the charged amino
acids in the vicinity of the cysteine thiol [37]. While this
phenomenon has been demonstrated in a few proteins (e.g.,
MAT, 14-3-3h, CLIC4) [19,25,36,37], our data, with its larger
collection of structures, further enhances the idea of an
autocatalytic mechanism, at least in half of the cases. Finally,
analysis on the mapped structures revealed that nitrosylation
might affect the specific function of some proteins. In the 24
mapped structures, the function of several proteins has previously
been demonstrated to be affected by nitrosylation. For example, in
GAPDH, nitrosylation of C152, which is in the NAD binding
pocket, has been shown to abolish the catalytic activity of GAPDH
Figure 6. Crystal structure of the representative protein-SNOs. A) An example of a buried S-nitrosylation site in a crystal structure of the
human protein disulfide-isomerase, PDIA3 (PDB code 3F8U), with positively charged (R280) and negatively charged (E216) residues in direct spatial
proximity of the nitrosylated cysteine (C244). B) An example of an S-nitrosylation site in direct contact with a ligand and thus likely disrupting/
affecting ligand binding upon nitrosylation. One of such examples is EGFR, which is shown here in complex with the monoclonal antibody inhibitor
cetuximab (PDB structure 1YY9). Binding of the antibody partially occludes the ligand-binding site in EGFR and keeps it in an inactive conformation.
As can be seen from the figure, the targeted cysteine (highlighted using red stick model) directly supports the protein interaction interface in EGFR,
suggesting that S-nitrolysation may attenuate its interactions with ligands and inhibitors. C) An example of S-nitrosylation site(s) located within
protein-protein (oligomerization) interfaces and that thus may disrupt/attenuate complex formation in PCNA and its function in DNA replication.
Note that DNA, which occupies the central hole in the PCNA trimer, is not included in this complex (PDB structure 1VYJ). On the other hand, p21
peptides, which mediate regulatory interactions with CDK/cyclin complexes, are shown using cartoon models.
doi:10.1371/journal.pone.0009075.g006
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also identified some new SNO sites, including those in EGFR and
PCNA. The kinase activity of EGFR has previously been shown to
be affected by NO [46,47]. Structural analysis revealed that one of
the SNO sites is involved in the ligand-binding surface of EGFR,
and nitrosylation of this site may affect its ligand binding. For
PCNA, since C81 is located at the trimer interface of PCNA,
nitrosylation of this site may affect the trimerization/stability of the
trimer ring formation. Although functional assays are necessary to
confirm these hypotheses, mapping of SNOs into structures
represents a strategy for predicting functional SNOs.
Considering that several groups have demonstrated the effects
of NO on cell proliferation, migration, motility, adhesion, and
aggressiveness in PCa cells [13,14,48], we decided to focus on a
subset of protein-SNOs we identified that are related to cancer
initiation and progression. We confirmed, by western-blot
analysis, a total of six representative proteins, including the
proliferating cell nuclear antigen (PCNA), karyopherin-b, a-
catenin, integrin b4, maspin, and eEF1A1. PCNA is critical
during chromosomal DNA replication; it has been found to be
overexpressed in various types of cancers and that its expression is
associated with poor survival outcomes [49]. Karyopherin-b1i s
instrumental in nucleo-cytoplasmic transport of signaling mole-
cules. It is overexpressed in cervical cancer [50], and its down-
regulation impairs cell proliferation [51]. Integrin b4i sa
transmembrane protein expressed predominantly on hemidesmo-
somes of epithelial cells. Similar to other members of the integrin
family, integrin b4 mediates anchorage and migration of normal
and cancer cells via influencing cell-matrix and cell-cell interac-
tions [52]. a-Catenin forms the link between the b-catenin/E-
cadherin complex and the actin cytoskeleton, hence playing a key
role in maintaining cell adhesion [53]. Loss of integrins and
catenins has been found in primary and metastatic PCa [54].
Maspin is a 42-kDa serine protease inhibitor with multifaceted
tumor suppressive activities in breast, prostate, colon, and oral
squamous cancers. Of interest is its biphasic expression pattern
during carcinogenesis, with a loss of expression during early steps
of tumorigenicity and re-expression in metastatic cancer [55].
Maspin-transfected PCa cells exhibit reduced tumorigenicity,
vasculature, and metastatic potential under hypoxic conditions
[56]. The eEF1 subunit 1A1 is involved in the binding of tRNA to
ribosomes during protein synthesis. It has been found to be
overexpressed in PCa [57] and implicated in tumorigenesis, signal
transduction, and apoptosis [58]. While the effect of NO in the
pathogenesis of BPH and PCa is unclear, our findings are
concordant with the fact that signaling molecules important in
cancer development are targets of nitrosylation and therefore may
be involved in NS-induced initiation of the NPrEC. Although a
number of apoptotic or cell cycle–related proteins whose activity
or stability can be modulated by S-nitrosylation [17], SNO-Bcl-2
was shown to promote the malignant transformation of lung
epithelial cells [59], supporting the role of NS in tumorigenesis
[59,60]. It is conceivable that the previously reported over-
expression of iNOS [4–7], together with other oxidative insults
[61], in the prostate epithelial and stromal compartments is likely
to cause nitrosylation of the above mentioned protein targets,
leading to modulation of cell growth, disruption of cellular
architecture, and/or transformation of normal epithelial cells of
the prostate.
Over-expression of NOS has been shown to promote
tumorigenicity in other cancers, and the therapeutic application
of NOS inhibitors for chemopreventive purposes has been the
subject of intense research for the past decade [62]. Inhibition of
NOS was recently shown to have tumor antivascular activity in
patients with PCa [63], and the efficacy of NO-releasing drugs for
BPH and lower urinary tract symptomatology was evaluated in a
clinical trial based on the rationale that NO can relax muscular
tone [64]. Given that the emerging evidence suggesting the
importance of NS in carcinogenesis and inflammation-related
diseases [59,60], further elucidation of the functional significance
of the targets identified in the present study should not only yield
insights into details of the complex role of NO and inflammation-
related prostatic diseases but also provide the experimental basis
for NOS-related therapeutics.
Supporting Information
Table S1 Table S1A identifies protein SNOs in both indepen-
dent protein pull-down experiments. Table S1B identifies protein
SNOs in one of the two protein pull-down experiments with the
corresponding peptide SNO(s) identified in peptide pull-down.
Found at: doi:10.1371/journal.pone.0009075.s001 (0.14 MB
PDF)
Table S2 Mapping SNO sites into high-resolution Protein Data
Bank (PDB) structures. Entrez gene symbols, gene names, PDB
codes (and chain letters, assumed to be A if not given), and the
number of S-nitrosylated cysteine residues in those structures are
given, respectively.
Found at: doi:10.1371/journal.pone.0009075.s002 (0.03 MB
PDF)
Table S3 Analysis of structural features (secondary structure and
solvent accessibility) of the 42 SNO sites mapped into 24 Protein
Data Bank structures.
Found at: doi:10.1371/journal.pone.0009075.s003 (0.05 MB
PDF)
Table S4 Localization of neighboring charged residues in the
vicinity of the SNO. Residues and atoms in contact with SNO
cysteines in the mapped structures were identified with the
iMolTalk server (http://i.moltalk.org) and the Loopp program,
using a cutoff distance of 5 A ˚ from the sulfur atom of the cysteine.
Found at: doi:10.1371/journal.pone.0009075.s004 (2.47 MB
PDF)
Figure S1 MS/MS spectra for all the biotinylated peptides
identified. The MS/MS spectra of biotinylated peptides were
evaluated by Scaffold (Proteome Software).
Found at: doi:10.1371/journal.pone.0009075.s005 (1.67 MB
PDF)
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